H.C. Wainwright Thinks Vascular Biogenics’ Stock is Going to Recover

By Carrie Williams

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vascular Biogenics (VBLTResearch Report) today and set a price target of $3. The company’s shares closed yesterday at $1.16, close to its 52-week low of $0.60.

Ramakanth observed:

“We maintain our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying a 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 29.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.

Vascular Biogenics has an analyst consensus of Moderate Buy, with a price target consensus of $3.

See today’s analyst top recommended stocks >>

Based on Vascular Biogenics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.35 million. In comparison, last year the company had a net profit of $6.31 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.